KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Misoprostol as Oral Solution or Oral Tablet for Induction of Labour (MISOBEST): A Randomised Controlled Non-Inferiority Trial.

Elin Svensk, Emelie Bessfelt, Sophia Brismar Wendel, Helena Kopp Kallner, Tove Wallström

BJOG 132(3) 288-296

PMID39440409
PMCIDPMC11704078
DOI10.1111/1471-0528.17986
发表日期2024-10-23
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

OBJECTIVE: To assess if off-label oral solution of misoprostol compared with licensed oral tablet of misoprostol approved for induction of labour (IOL) is as efficient in resulting in vaginal delivery within 24 h, using a non-inferiority design. DESIGN: Prospective, randomised, non-inferiority, open-label, blinded endpoint trial. SETTING: Two tertiary level hospitals, Stockholm, Sweden, January 2022 to May 2023. POPULATION: In all, 874 women, without previous caesarean section, with an unripe cervix and a singleton, cephalic foetus at 37 + 0 to 42 + 0 gestational weeks, with a normal cardiotocography, planned for IOL were included. METHODS: Women were randomised 1:1 to intervention (25 μg oral solution of misoprostol) or control (25 μg oral tablet of misoprostol) two-hourly for a maximum of eight doses. Subsequent methods of induction followed clinical practice. MAIN OUTCOME MEASURES: The primary outcome was vaginal delivery within 24 h tested using non-inferiority testing procedures at a non-inferiority margin of 5 percentage points. Secondary efficacy outcomes were tested for superiority of either treatment. Analyses were by intention-to-treat. RESULTS: There were 207 (47.4%) vaginal deliveries within 24 h for women receiving oral solution and 192 (43.9%) vaginal deliveries within 24 h for women receiving oral tablet, establishing non-inferiority with an absolute risk difference of 3.4% (95% CI -3.2% to 10.0%). Women receiving oral solution required fewer doses to reach active labour than women receiving oral tablet (5.7 vs. 6.1, p = 0.007). There were no significant differences for other secondary or safety outcomes. CONCLUSIONS: Off-label oral solution of misoprostol was non-inferior to the licensed oral tablet regarding efficacy of IOL defined as vaginal delivery within 24 h. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT05424445.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。